Attached files
| file | filename |
|---|---|
| 8-K - OSI PHARMACEUTICALS INC | v170891_8k.htm |
| EX-99.1 - PRESS RELEASE DATED DECEMBER 16, 2009. - OSI PHARMACEUTICALS INC | v170891_ex99-1.htm |
| EX-99.2 - PRESS RELEASE DATED DECEMBER 22, 2009. - OSI PHARMACEUTICALS INC | v170891_ex99-2.htm |
Exhibit
99.3
|
NEWS
RELEASE
|
||
|
Contacts:
|
||
|
OSI Pharmaceuticals,
Inc.
|
Burns
McClellan, Inc. (representing OSI)
|
|
|
Kathy
Galante (investors/media)
|
Justin
Jackson/Kathy Nugent (media)
|
|
|
Senior
Director
|
(212)
213-0006
|
|
|
631-962-2043
|
||
|
Kim
Wittig (media)
|
||
|
Director
|
||
|
631-962-2135
|
U.S.
Patent and Trademark Office Grants Reissued Patent Replacing OSI
Pharmaceuticals’ Tarceva®
Composition of Matter Patent
MELVILLE, NEW YORK – December 29,
2009 – OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced that the
U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065,
replacing Tarceva’s®
(erlotinib) composition of matter patent
(formerly No.5,747,498). The Company had applied for the
reissue patent in February 2008, and on September 17, 2009 the Company had
announced that the PTO had issued a “Notice of Allowance” accepting the
Company’s application to correct certain errors relating to the claiming of
compounds, other than Tarceva, which had fallen outside of the scope of the main
claim of the patent. The reissue patent will have the same November
18, 2018 expiration date (excluding any potential six-month pediatric
exclusivity period) as the original ‘498 patent.
“We
believe the reissue of the Tarceva patent, which now includes a claim that
solely identifies Tarceva, is a highly successful outcome,” stated Colin
Goddard, Ph.D., Chief Executive Officer of OSI Pharmaceuticals. “In
addition, we view this reissue grant as a positive step in managing generic
challenges to the Tarceva patent estate.”
About OSI
Pharmaceuticals
OSI
Pharmaceuticals is committed to "shaping medicine and changing lives" by
discovering, developing and commercializing high-quality, novel and
differentiated targeted medicines designed to extend life and improve the
quality of life for patients with cancer and diabetes/obesity.
This
news release contains forward-looking statements. These statements are subject
to known and unknown risks and uncertainties that may cause actual future
experience and results to differ materially from the statements
made. Factors that might cause such a difference include, among
others, OSI's and its collaborators' abilities to effectively market and sell
Tarceva and to expand the approved indications for Tarceva, OSI’s ability to
protect its intellectual property rights, safety concerns regarding
Tarceva, competition to Tarceva and OSI’s drug
candidates from other biotechnology and pharmaceutical
companies, the completion of clinical trials, the effects of FDA and other
governmental regulation, including pricing controls, OSI's ability to
successfully develop and commercialize drug candidates, and other factors
described in OSI Pharmaceuticals' filings with the Securities and Exchange
Commission.
###